This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colorectal cancer	Peroxisome proliferator- activated receptor- δ (PPAR δ ; PPAR δ)	<p>Studies in mice suggest that inhibiting PPARδ could be useful for treating colorectal cancer. Following azoxymethane induction of colon tumors, mice with colon epithelial cell-specific deletion of PPARδ developed 98.5% fewer tumors than wild-type mice ($p < 0.001$). Next steps include investigating the contribution of stromal cell-specific PPARδ expression to tumorigenesis and tumor angiogenesis.</p> <p>SAR351034, a PPARδ agonist from sanofi-aventis Group, is in Phase I to treat diabetes and dyslipidemia.</p> <p>CER-002, a second-generation PPARδ agonist from Cerenis Therapeutics S.A., is in Phase I testing to treat atherosclerosis.</p> <p>SciBX 2(20); doi:10.1038/scibx.2009.824 Published online May 21, 2009</p>	Unpatented; unlicensed	<p>Zuo, X. <i>et al. J. Natl. Cancer Inst.</i>; published online May 12, 2009; doi:10.1093/jnci/djp078</p> <p>Contact: Imad Shureiqi, The University of Texas M. D. Anderson Cancer Center, Houston, Texas e-mail: ishureiqi@mdanderson.org</p>